Rhenman & Partners Asset Management AB
Q1 2014 13F-HR Holdings
Net value change ($000)
+77,509
(30.3%)
New positions
20
Sold out positions
13
Turnover %
27.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| PFE | 11,338 | NEW |
| ALXN | 10,345 | 155.5% |
| GILD | 9,434 | 115.2% |
| MEDIVATION | 6,727 | NEW |
| REGN | 6,569 | 64.5% |
| Actavis Plc | 5,249 | NEW |
| CARDINAL FINANCIAL CORP | 5,032 | NEW |
| BIIB | 5,002 | 66.2% |
| ABBV | 4,394 | NEW |
| SYK | 4,163 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| THERAVANCE INC | -4,706 | -100.0% |
| ISRG | -3,073 | -100.0% |
| ARIAD PHARMACEUTICALS INC | -2,857 | -59.8% |
| ZBH | -2,796 | -100.0% |
| AETNA INC NEW | -2,744 | -100.0% |
| NPS PHARMACEUTICALS INC | -2,289 | -31.4% |
| A | -2,288 | -100.0% |
| *AEGERION PHARMACEUTICALS INC | -2,168 | -40.7% |
| IART | -2,147 | -100.0% |
| Medtronic PLC | -1,878 | -43.6% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
4,912
(1.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|